Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13
DUBLIN, Ireland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical…
DUBLIN, Ireland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq:…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq:…
SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic…
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic…
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the…
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the…
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza…
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza…
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
Interstitial Lung Disease Experts Present Forced Vital Capacity Results from ATLAS Study Seattle, Sept. 07,…
Interstitial Lung Disease Experts Present Forced Vital Capacity Results from ATLAS Study Seattle, Sept. 07,…
Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot…